Plain-English translation of NCT06581900 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at how MEOPA, a pain-relief gas used to help children with sickle cell disease during painful crises, may affect their vitamin B12 levels. Researchers want to understand whether exposure to this gas causes vitamin B12 deficiency in some patients, and if so, how much exposure is needed and which children might be at higher risk.
Vitamin B12 is essential for healthy nerves and DNA, but this medication can interfere with how your body uses it. A few patients have developed serious B12-related symptoms, but doctors don't yet know how much exposure causes problems or who is most vulnerable—information that could guide safer pain management for children with sickle cell disease.
You likely qualify if…
You likely don't qualify if…
When you arrive at the hospital for a sickle cell pain crisis, you'll be asked to participate. A small blood sample (about 1 teaspoon) and a urine sample will be collected along with your regular hospital blood work when you arrive and again when you leave. During your stay, doctors will track your pain management and do daily neurological check-ups, noting how much of the pain-relief gas you receive. The whole study is completed during your hospital visit.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France
Enrollment target
~29 participants
Started
November 2024
Primary completion
November 2026
Age range
2 Years – 18 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Claire PLUCHART, MD
CHU de Reims
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.